Toll Free: 1-888-928-9744

Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Alexion Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alexion Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Alexion Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Alexion Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Alexion Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Alexion Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Alexion Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Alexion Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Alexion Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alexion Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Alexion Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Alexion Pharmaceuticals, Inc. Snapshot 5
Alexion Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Alexion Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Alexion Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Alexion Pharmaceuticals, Inc. - Pipeline Products Glance 11
Alexion Pharmaceuticals, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Alexion Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Alexion Pharmaceuticals, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Alexion Pharmaceuticals, Inc. - Drug Profiles 15
eculizumab 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
asfotase alfa 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ALXN-1101 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ALXN-1007 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ALXN-1102 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ALXN-1103 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibody For Undisclosed Indication 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Alexion Pharmaceuticals, Inc. - Pipeline Analysis 24
Alexion Pharmaceuticals, Inc. - Pipeline Products by Target 24
Alexion Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 25
Alexion Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 26
Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 27
Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates 28
Alexion Pharmaceuticals, Inc. - Dormant Projects 36
Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products 37
Discontinued Pipeline Product Profiles 37
pexelizumab 37
Alexion Pharmaceuticals, Inc. - Company Statement 38
Alexion Pharmaceuticals, Inc. - Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53
List of Tables
Alexion Pharmaceuticals, Inc., Key Information 5
Alexion Pharmaceuticals, Inc., Key Facts 5
Alexion Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
Alexion Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Alexion Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Alexion Pharmaceuticals, Inc. - Phase III, 2014 11
Alexion Pharmaceuticals, Inc. - Phase II, 2014 12
Alexion Pharmaceuticals, Inc. - Phase I, 2014 13
Alexion Pharmaceuticals, Inc. - Preclinical, 2014 14
Alexion Pharmaceuticals, Inc. - Pipeline by Target, 2014 24
Alexion Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 25
Alexion Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 26
Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 27
Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 28
Alexion Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 36
Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 37
Alexion Pharmaceuticals, Inc., Other Locations 48
Alexion Pharmaceuticals, Inc., Subsidiaries 49 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify